TrialSignal transduction and targeted therapy2021

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.

Tao Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.